-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the evaluation results of adverse drug reactions, in order to further protect the safety of public medication, the National Medical Products Administration has decided to treat diammonium glycyrrhizinate preparations (including diammonium glycyrrhizinate injection, diammonium glycyrrhizinate injection, and diammonium glycyrrhizinate sodium chloride injection).
Liquid, diammonium glycyrrhizinate glucose injection, diammonium glycyrrhizinate capsules, diammonium glycyrrhizinate enteric-coated capsules and diammonium glycyrrhizinate enteric-coated tablets) The contents of the instructions will be revised uniformly
.
The relevant matters are hereby announced as follows: 1.
The marketing authorization holders of the above-mentioned drugs shall comply with the relevant provisions of the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the revised requirements of the instructions for diammonium glycyrrhizinate oral preparations and diammonium glycyrrhizinate injection preparations (see attachment) , Before December 2, 2021, report to the Drug Evaluation Center of the National Medical Products Administration or the provincial drug regulatory authority for record
.
If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
.
Drugs produced on the date of filing shall not continue to use the original drug instructions
.
The holder of the drug marketing authorization shall replace the instructions and labels of the drugs that have been shipped out of the factory within 9 months after filing
.
2.
The drug marketing license holder shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on drug use and safety issues, and guide physicians and pharmacists to use drugs rationally
.
3.
Clinicians and pharmacists should carefully read the revised contents of the above-mentioned drug inserts, and when choosing medications, they should conduct a sufficient benefit/risk analysis based on the newly revised inserts
.
4.
The patient should read the drug insert carefully before taking the medicine.
If using prescription drugs, they should strictly follow the doctor's advice
.
5.
The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law
.
Hereby announce
.
Attachment: Requirements for the revision of the instructions for diammonium glycyrrhizinate oral preparations and diammonium glycyrrhizinate injection preparations National Medical Products Administration September 3, 2021 National Medical Products Administration Announcement No.
107 in 2021 Annex.
docx
Liquid, diammonium glycyrrhizinate glucose injection, diammonium glycyrrhizinate capsules, diammonium glycyrrhizinate enteric-coated capsules and diammonium glycyrrhizinate enteric-coated tablets) The contents of the instructions will be revised uniformly
.
The relevant matters are hereby announced as follows: 1.
The marketing authorization holders of the above-mentioned drugs shall comply with the relevant provisions of the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the revised requirements of the instructions for diammonium glycyrrhizinate oral preparations and diammonium glycyrrhizinate injection preparations (see attachment) , Before December 2, 2021, report to the Drug Evaluation Center of the National Medical Products Administration or the provincial drug regulatory authority for record
.
If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
.
Drugs produced on the date of filing shall not continue to use the original drug instructions
.
The holder of the drug marketing authorization shall replace the instructions and labels of the drugs that have been shipped out of the factory within 9 months after filing
.
2.
The drug marketing license holder shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on drug use and safety issues, and guide physicians and pharmacists to use drugs rationally
.
3.
Clinicians and pharmacists should carefully read the revised contents of the above-mentioned drug inserts, and when choosing medications, they should conduct a sufficient benefit/risk analysis based on the newly revised inserts
.
4.
The patient should read the drug insert carefully before taking the medicine.
If using prescription drugs, they should strictly follow the doctor's advice
.
5.
The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law
.
Hereby announce
.
Attachment: Requirements for the revision of the instructions for diammonium glycyrrhizinate oral preparations and diammonium glycyrrhizinate injection preparations National Medical Products Administration September 3, 2021 National Medical Products Administration Announcement No.
107 in 2021 Annex.
docx
